Elsevier

Human Pathology

Volume 29, Issue 4, April 1998, Pages 421-424
Human Pathology

Case study
Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma

https://doi.org/10.1016/S0046-8177(98)90128-9Get rights and content

Abstract

Interleukin-6 (IL-6) is produced by renal cell carcinoma (RCC) cell lines and primary tumors. Using immunohistochemical staining in two RCC patients with hypercalcemia and high serum levels of free and total IL-6, we showed expression of IL-6 in metastatic bone tissue. The role of IL-6 in hypercalcemia and bone resorption would suggest that bisphosphonates or dexamethasone could be useful as adjuvant therapy for IL-6 dependant bone metastases which fail to respond to interferon alpha (IFN) α 2a and all trans retinoic acid (ATRA).

References (23)

  • JM Blay et al.

    Serum level of interleukin-6 as a pronostic factor in metastatic renal cell carcinoma

    Cancer Res

    (1992)
  • Cited by (18)

    View all citing articles on Scopus
    View full text